Treatment-driven dynamic modulation of theranostic targets after neoadjuvant therapy in resistant triple negative and HER2-positive breast cancer

Summarise with VIRAT
Authors: Francesca Patanè
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Over the past decades, the prognosis of early-stage breast cancer has improved significantly due to the introduction of increasingly effective systemic therapies; however, a subset of patients continues to face a high risk of recurrence, particularly in the presence of residual disease after neoadjuvant treatment. Post-neoadjuvant studies have shown that targeted treatment of resistant disease with non–cross-resistant agents can significantly improve clinical outcomes. Despite this, patient selection for these treatments remains largely empirical, relying almost exclusively on the presence of residual tumor rather than on the biological characteristics of the residual disease. This project aims to address this gap by performing an in-depth analysis of the tumor transcriptional profile before and after neoadjuvant therapy using paired tumor samples. The goal is to understand how the molecular landscape of breast cancer changes in response to treatment and to identify biological programs associated with resistance, prognosis, and clinical outcomes.

Fields of Study & Subjects

Breast Cancer Treatment Studies HER2/EGFR in Cancer Research Breast Lesions and Carcinomas

Publication details

Journal / source
Electronic Theses and Dissertations Repository (University of Pisa)
Publication date
22 January 2026
Language
IT
Document type
Thesis